Brawn Laboratories Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Brawn Laboratories Limited Pharmaceutical Export Portfolio Dataset — 17 Products, $22.6M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Brawn Laboratories Limited — Pharmaceutical Exporter Profile (2026) | 17 Products, $22.6M Trade | TransData Nexus

Brawn Laboratories Limited

Indian Pharmaceutical Exporter · Antibiotics Specialist · $22.6M Total Trade · DGFT Verified

Brawn Laboratories Limited is an Indian pharmaceutical exporter with a total trade value of $22.6M across 17 products in 10 therapeutic categories. Based on 673 verified export shipments from Indian Customs (DGFT) records, Brawn Laboratories Limited is the #1 Indian exporter in 1 product including Roxithromycin. Top exports include Enoxaparin ($3.6M), Ciprofloxacin ($3.4M), Syringe ($3.1M).

Brawn Laboratories Limited — Export Portfolio & Destination Treemap

Brawn Laboratories Limited pharmaceutical export portfolio — 17 products across 10 therapeutic categories. Source: Indian Customs (DGFT).

Who is Brawn Laboratories Limited? — Company Overview & Market Position

Brawn Laboratories Limited, established on March 27, 1990, is a public limited company headquartered in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U73200DL1990PLC039653. As of the latest available data, Brawn Laboratories has an authorized capital of ₹10 million and a paid-up capital of ₹9.95 million. The company operates in the pharmaceutical sector, focusing on the manufacture and export of finished pharmaceutical formulations. Brawn Laboratories has a significant presence in over 60 countries, including regions such as Southeast Asia, Latin America, Africa, the Middle East, and the Commonwealth of Independent States (CIS).

What Does Brawn Laboratories Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Enoxaparin$3.6M 2Ciprofloxacin$3.4M

Product Portfolio — Top 17 by Export Value

Brawn Laboratories Limited exports 17 pharmaceutical products across 10 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Enoxaparin	Cardiovascular	$3.6M	72	1.7%	5
2	Ciprofloxacin	Antibiotics	$3.4M	67	1.1%	14
3	Syringe	Medical Devices & Diagnostics	$3.1M	62	1.7%	8
4	Cephalexin	Antibiotics	$2.3M	70	0.7%	11
5	Colchicine	Lipid & Metabolism	$1.6M	40	7.6%	3
6	Albendazole	Antimalarial & Antiparasitic	$1.4M	84	1.9%	11
7	Hydrocortisone	Corticosteroids	$1.2M	53	1.9%	10
8	Phenylephrine	Respiratory & OTC	$1.1M	44	1.3%	13
9	Doxycycline	Antibiotics	$951.3K	31	0.8%	15
10	Guaifenesin	Respiratory & OTC	$793.2K	24	3.0%	4
11	Amikacin	Advanced Antibiotics	$750.0K	15	3.6%	6
12	Meloxicam	Analgesics & Antipyretics	$738.4K	32	0.4%	12
13	Roxithromycin	Advanced Antibiotics	$700.0K	14	16.8%	1
14	Ranitidine	Gastrointestinal	$313.1K	28	2.5%	9
15	Tetracycline	Antibiotics	$288.8K	8	1.7%	12
16	Tinidazole	Advanced Antibiotics	$259.8K	19	1.4%	15
17	Warfarin	Cardiovascular	$29.7K	10	0.4%	13

Brawn Laboratories Limited exports 17 pharmaceutical products across 10 therapeutic categories with a total export value of $22.6M. The company is the #1 Indian exporter in 1 product: Roxithromycin. The top category is Antibiotics (30.6% of portfolio), followed by Cardiovascular (16.1%), indicating a concentrated portfolio with the top 5 products accounting for 62.0% of total export value.

Brawn Laboratories Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Brawn Laboratories operates a state-of-the-art manufacturing facility located in Faridabad, approximately 30 kilometers from New Delhi. The plant spans over 125,000 square feet and is equipped with three separate blocks dedicated to the production of non-beta, cephalosporin, and penicillin products. This setup enables the company to manufacture a wide range of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The facility adheres to Good Manufacturing Practices (GMP) and holds ISO 9001:2008 certification, ensuring high-quality production standards.

3Key Leadership

The leadership team at Brawn Laboratories Limited comprises several key individuals:

Brij Raj Gupta: Chairman & Managing Director, appointed on April 23, 2003.

Adarsh Kumar Gupta: Director, appointed on April 23, 2001.

Love Gupta: Director, appointed on October 5, 2010.

Bal Kishan Sharma: Director, appointed on March 28, 2015.

Rajveer Singh: Director, appointed on October 5, 2010.

Rakesh Kumar Dhama: Director, appointed on October 5, 2010.

Nanak Singh Rana: Director, appointed on September 30, 2014.

Urmila Gupta: Director, appointed on April 28, 2006.

Brij Bala Gupta: Director, appointed on October 3, 2003.

Trilok Singh: Director, appointed on March 28, 2015.

Ashish Yadav Kumar: Director, appointed on July 16, 2018.

These individuals collectively guide the strategic direction and operations of Brawn Laboratories Limited.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Brawn Laboratories Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Brawn Laboratories Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained regulatory approvals for its products in these regions, facilitating market access and distribution. Brawn Laboratories has been awarded WHO-GMP and ISO 9001:2008 certifications, which are recognized internationally and support its entry into these regulated markets. The company's adherence to international quality standards enhances its credibility and acceptance in these markets.

2Emerging Markets

Brawn Laboratories Limited has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company has established its own offices in countries such as Vietnam, Philippines, Myanmar, Ethiopia, and Congo, with plans to inaugurate an office in Panama. This strategic expansion enables Brawn Laboratories to strengthen its relationships with local partners and navigate the regulatory landscapes of these regions effectively. The company's commitment to long-term business relationships facilitates a deeper understanding of local market dynamics and consumer needs.

3Geographic Strategy

Brawn Laboratories Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Brawn Laboratories Limited has registered its manufacturing facility with the U.S. Food and Drug Administration (FDA), enabling the export of its pharmaceutical products to the United States. The company has filed Abbreviated New Drug Applications (ANDAs) for several of its products, seeking approval for marketing in the U.S. market. Brawn Laboratories has also submitted Drug Master Files (DMFs) to the FDA, providing detailed information about the manufacturing processes and quality controls of its products. The company's facility has undergone FDA inspections, and it has received Establishment Inspection Reports (EIRs) indicating compliance with FDA regulations. These actions demonstrate Brawn Laboratories' commitment to meeting the stringent requirements of the U.S. pharmaceutical market.

2WHO & EU GMP

Brawn Laboratories Limited holds Good Manufacturing Practices (GMP) certifications from the World Health Organization (WHO) and the European Union (EU). These certifications affirm the company's adherence to international quality standards in the manufacturing of pharmaceutical products. The WHO-GMP certification is particularly significant for accessing markets in developing countries, as it is recognized by the World Health Organization. The EU GMP certification facilitates the company's entry into European markets, ensuring that its products meet the rigorous quality standards required by EU regulations.

Brawn Laboratories Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Brawn Laboratories Limited operates in a competitive pharmaceutical industry, facing competition from both domestic and international companies. In the generic pharmaceutical segment, competitors include companies like Laurus Labs, Symbiotec, and SeQuent. In the branded pharmaceutical segment, the company competes with established players in various therapeutic categories. Brawn Laboratories differentiates itself through its extensive product portfolio, international certifications, and a strong presence in emerging markets. The company's focus on quality manufacturing and regulatory compliance enhances its competitiveness in the global market.

2Key Differentiators

Brawn Laboratories Limited's key differentiators include its comprehensive product portfolio covering a wide range of therapeutic segments, adherence to international quality standards such as WHO-GMP and ISO 9001:2008 certifications, and a diversified geographic presence across over 60 countries. The company's state-of-the-art manufacturing facility in Faridabad, equipped with advanced technology and dedicated production blocks, further distinguishes it in the industry. Additionally, Brawn Laboratories' commitment to long-term business relationships and its proactive approach to regulatory compliance contribute to its unique position in the market.

Strategic Position

Buyer Due Diligence Brief — Evaluating Brawn Laboratories Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Brawn Laboratories Limited has a track record of consistent export performance, with a total export value of $22.6 million USD and 673 shipments across 17 products in 10 therapeutic categories. The company's top five products—Enoxaparin, Ciprofloxacin, Syringe, Cephalexin, and Colchicine—account for 62% of its export portfolio, indicating a focused approach to product offerings. The company's adherence to international quality standards and certifications, along with its diversified geographic presence, underscores its reliability as a supplier in the pharmaceutical industry.

2Certifications to Verify

Importers should verify the following certifications when considering Brawn Laboratories Limited as a supplier:

FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration (FDA) to ensure compliance with U.S.

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Brawn Laboratories Limited

How many pharmaceutical products does Brawn Laboratories Limited export from India?

Brawn Laboratories Limited exports 17 pharmaceutical products across 10 therapeutic categories. The top exports are Enoxaparin ($3.6M), Ciprofloxacin ($3.4M), Syringe ($3.1M), Cephalexin ($2.3M), Colchicine ($1.6M). Total export value is $22.6M.

What is Brawn Laboratories Limited's total pharmaceutical export value?

Brawn Laboratories Limited's total pharmaceutical export value is $22.6M, based on 673 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Brawn Laboratories Limited the #1 Indian exporter?

Brawn Laboratories Limited is the #1 Indian exporter in 1 products: Roxithromycin (16.8% market share).

What therapeutic categories does Brawn Laboratories Limited cover?

Brawn Laboratories Limited exports across 10 therapeutic categories. The largest are Antibiotics (30.6%, 4 products), Cardiovascular (16.1%, 2 products), Medical Devices & Diagnostics (13.7%, 1 products).

Get Full Brawn Laboratories Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.